Our results show that EPI has therapeutic activity that is similar to that of DOX in patients with advanced breast cancer , and that EPI is a less cardiotoxic drug than DOX , even accounting for the difference in myelosuppressive potency .
In this study , EPI had therapeutic activity in breast cancer similar to DOX , but produced less cardiotoxicity than the parent compound .
DOXORUBICIN (DOX) , or Adriamycin (Adria Laboratories , Columbus , Ohio) , is one of the most useful antineoplastic agents available .
